AqT™ Therapeutics

One of the main goals of developing AqT™ linkers and polymers is for drug conjugation and delivery. Please visit to learn more about these applications. Customers who wish to develop their own proprietary therapeutics based on AqT linkers and polymers are encouraged to contact us for how to access these technologies.

AqT™ Antibody Drug Conjugate (ADC) and Protein Drug Conjugate (PDC) Evaluation Kits

AqT™ linkers are novel proprietary biomaterials invented at CellMosaic that are chemically assembled from a class of natural and edible sugar alcohol compounds with properties by design. AqT™ linkers can be designed to label antibodies or proteins with very hydrophobic drugs to improve the overall performance of an ADC or PDC as a safer and more effective drug.

Solely to facilitate the Customer’s evaluation of CellMosaic’s Proprietary Materials for Customer’s internal development and drug screening, CellMosaic has developed some small scale Proprietary Evaluation Kits for labeling customer's antibody or protein at CellMosaic, and to evaluate the benefit of such Proprietary Material on the drug performance in vitro. The transfer and usage of these conjugates with proprietary linker are governed exclusively by the General Terms and Conditions for Material Transfer of AqueaTether™ (AqT™) Antibody Drug Conjugate (ADC) and Protein Drug Conjugate (PDC) , and any supplemental terms set forth in the Quote(s) to which these Terms are attached. Please contact CellMosaic for a quote to access these evaluation kits.